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The aim of this work was to determine the presence of galectin-10 in nasal lavage ﬂuid (NLF) of patients with aspirin-sensitive
respiratory disease (ASRD) before and after challenge with L-ASA (aspirin) by ELISA. Fifteen ASRD patients, ten aspirin-tolerant
asthmatics (ATA), and ﬁfteen healthy controls (HC) were studied. The baseline presence of Galectin-10 in PBMC was determined
using real time PCR. Galectin-10 was evaluated in tissue of nasal polyps by western blot. Our results showed a lower expression
in PBMC of ASRD patients than in ATA and healthy controls. However, a higher concentration of galectin-10 in NLF was found
in ASRD patients before and after L-ASA challenge; western blot conﬁrmed a high expression of galectin-10 in tissue from nasal
polyps obtained from ASRD patients. Our results suggest a probable role of galectin-10 in the inﬂammatory response observed in
ASRD patients; however, conﬁrmatory studies are needed.
1.Introduction
Aspirin-sensitive respiratory disease (ASRD) is a clinical
syndrome characterized by a combination of nasal poly-
posis, chronic hypertrophic eosinophilic sinusitis, asthma
and intolerance to aspirin or other nonsteroidal anti-
inﬂammatory drugs (NSAIDs). Ingestion of aspirin (L-ASA)
and of most NSAIDs results in upper and/or lower res-
piratory reactions, including rhinitis, conjunctivitis, laryn-
gospasm and bronchospasm [1]. The earliest symptoms are
usually rhinorrhea with nasal congestion and progression
to the lower respiratory tract with asthma and ﬁnally nasal
polyposis [2]. In a study performed in the USA, the average
age of onset was reported as 34 years, and it may be acquired
between youth and mature age, with no ethnic predilection
and rare familial associations. ASRD is more commonly
reported in women than in men (57% versus 43%) [3].
Galectins are a growing family of β galactoside-binding
animallectins.Atleast12galectinsarepresentinhumans[4].
It has been proposed that some galectins are secreted by an
unorthodox mechanism to exert their extracellular function
[5].Thewidedistributionofgalectins,withrespecttospecies
andtissues,suggeststhattheyexertmanydiﬀerentfunctions.
The two most extensively studied galectins are galectin-1 and
galectin-3 [6], but little information exists about galectin-
10. It is well known that galectin-10 has been localized
only in eosinophils and basophils; [7] however, a recent
ﬁnding shows that galectin-10 is constitutively expressed in
CD4+CD25+ regulatory T-cells in addition to playing a role
for regulatory T cell function [8].2 The Scientiﬁc World Journal
Currently, the knowledge about the presence of some
galectins in epithelium, endothelium, and activiated tissue
macrophages, cells that are involved in inﬂammation, it has
led to many researchers to study the role of galectins in
inﬂammatory processes [9]. Taking into account that the
ASRD is a clinical syndrome associated with severe and
chronic inﬂammation in both upper and lower airways
and a recent ﬁnding [10], where the authors reported an
overexpression of galectin-10 mRNA in peripheral blood
of aspirin-induced asthma, we thought it was interesting
to investigate whether galectin-10 was released in the nasal
lavage ﬂuid of a group of patients with ASRD before
and after the challenge with the triggering agent (L-ASA)
and to analyze its probable participation in the associated
inﬂammatory process in ASRD.
2.MaterialandMethods
2.1. Subjects. Forty subjects from the Department of
Immunogenetics and Allergy of our Institute, participated
in this study, all of them were nonsmokers (Table 1). Their
atopic status was investigated by skin-prick testing with
diﬀerent allergens including DPT, cat and dog dander,
cocroach and trees-like Ligustrum vulgare or Alnus glutinosa.
Neither oral corticosteroids nor antileukotrienes were given
to patients 4 weeks before the study and β2-agonists
were withdrawn 48Ih before the study. Aspirin (L-ASA)-
sensitivity was established by clinical history and a nasal
L-ASA challenge [11]. Before the challenge, all patients
were examined with anterior rhinoscopy to evaluate the
presence of nasal polyps. Five of the 15 L-ASA sensitive
patients had small nasal polyps (Lund-Mackay score =
1). Patients with nasal polyps grades 2 and 3 did not
participate in the study, because they could not undergo
reliable rhinomanometry measurements [12]. This study
was approved by the Institutional Ethics Committee and all
patients gave their signed informed consent.
2.2. Study Design. Subjects were divided into three groups:
(1) 15 L-ASA-sensitive asthmatics (ASRD), (2) 10 aspirin-
tolerant asthmatics (ATA), and (3) 15 healthy controls (HC).
The ASRD group had been diagnosed previously by both
clinical history and a positive response to a nasal L-ASA
challenge (from 25mg to 100mg, according to the clinical
response). A baseline nasal lavage and a peripheral blood
sample were carried out in all subjects during the screening
visit. Subsequently, nasal lavage ﬂuid (NLF) was obtained
pre- and postnasal challenge with L-ASA [13], which was
used for the detection of Galectin-10 by ELISA.
2.3. Nasal L-ASA Challenge. A nasal L-ASA challenge was
performed using a modiﬁed protocol described by Casade-
vall et al. [11]. The nasal challenge was performed with a
total dose of 25mg of L-ASA (Aspisol, Bayer Germany),
12.5mg L-ASA was instilled in each nostril and on each
inferior turbinate. The nasal response was evaluated by
rhinomanometry and clinical response by scoring the
subjective nasal symptoms using a visual analogue scale
ranging from 0 (no symptoms) to 30 (severe symptoms)
as described previously [14]. The clinical symptoms score
included rhinorrhea, nasal blockage, itching of the nose,
and palate and/or throat and sneezing. The positive nasal
reaction was deﬁned as the appearance of nasal symptoms
such as rhinorrhea, nasal congestion, sneezing, and a 25%
decrease of the total nasal ﬂow value, as compared with
the baseline measurement or a 40% bilateral decline of
inspiratory nasal ﬂow, as compared with the baseline value
assessed by rhinomanometry. Subjects with baseline nasal
inspiratory ﬂow of 250mL/s did not participate in the study.
The bronchial response was also evaluated by performing
spirometry.
Nasal lavage ﬂuid (NLF), blood, and tissue specimens
fromHC,ATA,andASRDsubjectswerecollectedunderrules
approved by the institutional Bioethics Committee.
2.4. mRNA Expression by Quantitative Real-Time RT-PCR.
RNA was extracted from 8 × 106 PBMC using TRIZOL
(GibcoBRL,Gaithersburg,MD)accordingtomanufacturer’s
instructions. RNA was reverse transcribed into cDNA using
the ThermoScript RT-PCR system (Invitrogen, Carlsbad,
CA, USA). Galectin-10 mRNA levels were quantiﬁed by real-
time RT-PCR (qRT-PCR) using TaqMan Gene Expression
Assay (Applied Biosystems, Tokio, Japan) on a StepOnePlus
Real-Time PCR System (Applied Biosystems) according
to manufacturer’s instructions. The relative quantiﬁcation
method[15]wasusedtomeasuretheamountsofGalecin-10,
normalized to 18s rRNA as endogenous control. The results
were analyzed with the software ABI PRISM 7700 Sequence
Detection System.
2.5. Double Antibody Solid Phase Immunoassay (ELISA).
Measurement of galectin-10 was performed using a double
antibody solid phase immunoassay (ELISA) developed in
our laboratory. A human eosinophil cellular protein extract
from a patient’s blood with eosinophilia was used as
positive control a human. Brieﬂy, a monoclonal antibody
to galectin-10 (Abcam, Cambridge UK) was incubated
overnight at 4◦Ci na ni m m u n o s o r b e n tp l a t e( R & DS y s t e m s ,
Minneapolis MN, USA). The plate was blocked with BSA
(1%, 2h, RT), and 100μL of nasal lavage ﬂuid (NLF)
or positive control was added, each sample was evaluated
in triplicate and incubated overnight at 4◦C. Later, the
plate was washed four times with phosphate-buﬀer saline
(PBS) containing 0.05% Tween 20 and then, polyclonal goat
antihuman galectin-10 antibody 1:100 (R&D Systems) was
added to each well (2h). After washing with PBS-Tween
20, we added a conjugate of donkey anti-goat biotinylated
1:300 (Sigma St. Louis, MO, USA) (2h, RT). To evidence
the reaction, 100μL/well of ExtrAvidin-Peroxidase 1:500
(Sigma) was added for 30 minutes. The plate was washed
again and the immunoenzymatic reaction was revealed with
tetramethylbenzidine (TMB) substrate (Sigma-Aldrich St.
Louis, MO, USA). The absorbance was measured at 450nm
in an ELISA plate reader (Benchmark, Bio-Rad, Hercules,
CA,USA).The Scientiﬁc World Journal 3
Table 1: Clinical characteristics of the study group.
HC ATA ASRD
Subjects (n)1 5 1 0 1 5
AGE (years) 23 (21–34) 39 (14–62) 47 (28–74)
GenderM:F 8:7 4:6 2:13
Atopic (%) 0 30 47
Blood Eosinophiis (×103/mm3)0 .17 ±0.16 0.52 ±0.26 0.50 ±0.42
∗
IgE (IU/mL) 76.8 ±65.4 229.5 ±438.2 267.8 ±320.7
Lisil-aspirin challenge (+) 0 0 15
Methacholine PC20 (mg/mL) >32 3.0 ±22 .5 ±1
Mean basal FEV (% predicted) 107 ±6 103 ±22 97 ±12
HC: Healthy Controls.
ATA: Aspirin-Tolerant Asthmatics.
ASRD: Aspirin-Sensitive Respiratory Disease patients.
FEV: Forced-expiratory-volume.
∗P>0.05 ASRD versus ATA.
2.6. Western Blot. To evaluate the presence of galectin-10 in
tissuesamples,weperformedawesternblottwiththeprotein
extractofpolypsobtainedfromASRDandATApatients.Tis-
sue of nasal mucosa without inﬂammatory process was used
as negative control. Nasal tissue extracts were prepared with
coldlysisbuﬀer(2MTris,pH7.5,0.15MNaCl,0.05MNaF).
Each sample was centrifuged at 13,000rpm (Centrifuge
Hermle Z232K, Hermle LaborTechnik, GmbH, Germany)
for one minute at 4◦C. The supernatant was separated and
the total protein concentration was determined with the
Pierce BCA Protein assay kit (Thermo Scientiﬁc). Proteins
(previously adjusted to 30μg) were separated on 12% SDS
Laemmli gels [16]. After electrophoresis, the proteins were
transferred onto a polyvinyl diﬂuoride membrane (Bio-
Rad), the membrane was incubated with 3% BSA for 2
hours and then incubated with a monoclonal antibody
to galectin-10 (Abcam, Cambridge, UK, 1:200) overnight
at 4◦C. Immunodetection was performed incubating with
a monoclonal anti-mouse biotinylated antibody and the
Streptavidin-Peroxidase conjugate (1:1000) (Sigma) for
30 minutes; afterwards, the membrane was washed and
incubated with DAB (Vector Laboratories, Burlingame, CA,
USA).
2.7. Statistical Analysis. Statistical analysis was performed
using Mann Whitney test, (GraphPad Prism 5, from Graph-
Pad software, Inc. CA, USA). P ≤ 0.05 was considered
statistically signiﬁcant. A post-hoc analysis of the sample size
using G power (version 3.0.10) showed that 15 ASRD and 10
ATA subjects would have suﬃcient power (80%) to test our
hypothesis.
3. Results
3.1. Clinical Findings. Intranasal challenge with L-ASA-
induced rhinorrhea, nasal congestion, and sneezing symp-
toms lasted up to 2h in all ASA-sensitive patients. Following
L-ASA challenge, a signiﬁcant decline in the mean nasal
inspiratory ﬂow in ASA-sensitive patients was observed.
Absence of clinical response to L-ASA was observed in
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HC ATA ASRD
R
U
4
3
2
1
0
Figure 1: Relative quantiﬁcation (RU:Relative Units) of galectin-
10 gene expression in PBMC with respect to healthy controls (HC)
in patients with aspirin sensitive respiratory disease (ASRD) and
aspirin-tolerant asthma (ATA).
both aspirin-tolerant asthmatics (ATA) and healthy controls
(HC).
3.2. Gene-Expression of Galectin-10. We analyzed the galec-
tin-10geneexpressioninPBMCbyrealtimePCR(Figure 1).
The values were determined with respect to the healthy
controls.Alowerexpressionofgalectin-10genewasobserved
in ASRD with respect to ATA patients (0.681 ± 0.733 versus
1.262 ±1.107).
3.3. Galectin-10 in Nasal Lavage Fluid. A higher baseline
concentration of galectin-10 was observed in the NLF from
ASRD and ATA patients with respect to the HC (0.045 ±
0.046, 0.034 ± 0.048 versus 0.015 ± 0.011, resp.) (Figure 2).4 The Scientiﬁc World Journal
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Figure 2: Determination of galectin-10 by ELISA at baseline in
nasal lavage ﬂuid of aspirin sensitive respiratory disease patients
(ASRD), aspirin-tolerant asthmatics (ATA) and healthy controls
(HC).
Interestingly, when we compared the pre- and postnasal L-
ASA-challenge galectin-10 levels, signiﬁcant diﬀerences in
the concentration of galectin-10 were observed (Figure 3)
(ASRD: 0.045 ± 0.046 versus 0.114 ± 0.064, ATA: 0.027 ±
0.039 versus 0.068 ± 0.059 and HC: 0.015 ± 0.010 versus
0.044 ± 0.014); these diﬀerences became more evident when
comparing between ASRD and ATA patients (P<0.0041
versus P<0.05).
3.4. Detection of Galecin-10 in Nasal Tissue by Immunoblot.
Galectin-10 expression in nasal tissue was investigated by
immunoblot using tissue from nasal polyps of ASRD and
ATA patients and comparing their values versus healthy
nasal mucosa tissue. Protein extract of eosinophils was
used as positive control (Figure 4). Nasal polyps from the
three diﬀerent patients with ASRD and ATA were evaluated.
Results show a higher expression of galectin-10 in patients
with ASRD when compared with ATA patients and healthy
nasal tissue. In healthy mucosa tissue, a lower galectin-10
expression was observed. This higher expression of galectin-
10 in patients with ASRD diagnosis may be probably a
consequence of the more aggressive inﬂammatory process
observed in this disease.
4. Discussion
This is the ﬁrst study that shows the release of galectin-10
in nasal ﬂuid lavage (NLF) of aspirin-sensitive respiratory
disease (ASRD) patients before and after nasally challenged
with L-ASA. The galectins family include 15 members [4,
17], which are β-galactosides-binding animal lectins [18].
Galectins have been associated with the innate and adaptive
immune function [19, 20], as well as with cancer, immunity,
andinﬂammatoryresponses[20,21].Galectin-10orCharcot
Leyden crystal protein (CLC) has been previously related
with the inﬂammatory process [6] and, recently also, it has
been found in patients with allergic rhinitis [22]. However,
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Figure 3: Comparison of galectin-10 levels before (b) and after (a)
nasal challenge with L-ASA in nasal ﬂuid lavage of aspirin-sensitive
respiratory disease patients (ASRD), aspirin-tolerant asthmatics
(ATA) and healthy controls (HC).
its function in the cell is still only partially understood. In
this work, the expression of galectin-10 by real time PCR was
determined in PBMC obtained from patients with ASRD.
Recently, Devouassoux and cols. (2008) [10]r e p o r t e da n
overexpression of mRNA galectin-10in wholeblood samples
from patients with ASRD in absence of challenge with L-
aspirin, and they suggested the importance of galectin-10
in the accurate diagnosis of aspirin-induced asthma. Our
results, however, showed a minor baseline expression of
galectin-10 in PBMC from ASRD patients. It is probable
that the observed diﬀerences in the expression of galectin-
10 could be an eﬀect of the puriﬁcation process of RNA
[23], or due to individual diﬀerences in the galectin-10 gene-
expression patterns as a product of the evaluated patient’s
age [24]. Additionally, it is important to highlight that the
diagnosis of ASRD in the group of patients sutudied by
Devouassoux was not made with the aspirin challenge test,
regarded as decisive for the correct diagnosis of ASRD [25].
In this investigation, we also analyzed the presence of
galectin-10 in healthy nasal tissue and nasal polyps extracts
from ASRD and ATA patients by western blot. Our results
showed a higher expression of galectin-10 in nasal polyps
of patients with ASRD with respect to the ATA or healthy
nasal tissue subjects. The presence of galectin-10 was con-
ﬁrmed using protein eosinophil extract as a positive control.
Previously, the galectin-10 protein had been found in diverse
tissues, body ﬂuids, or cells involved with the inﬂammatory
response, like eosinophils and basophils [26], as well as in
inﬂamed nasal tissue with allergic rhinitis [27]. However,
we do not know about any report about Galectin-10 in
nasal polyps of ASRD subjects. We know that the presence
of nasal polyps in ASRD is the ultimate manifestation of a
chronic inﬂamatory process with the presence of activated
eosinophils and mast cells [28]; therefore, we could infer that
galectin-10 could be helping to perpetuate the inﬂammatory
process in this site. It is relevant to mention that galectin-10
or Charcot-Leyden crystals contain the enzyme lysolecithin
acylhydrolase, which is one of several proteins involvedThe Scientiﬁc World Journal 5
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Figure 4: Western blot analysis of galectin-10 in supernatant of
lysed nasal polyp from an aspirin-tolerant asthma polyp (lane 1),
aspirin sensitive respiratory disease nasal polyps (lane 2, 4, and 5)
and nasal mucosa as a tissue control without inﬂammatory process
(lane 3). C(+) protein extract of eosinophils. (First lane, molecular
weight markers).
in the eosinophil’s immune functions [27]. Unfortunately,
this enzyme also has the ability to damage the respiratory
epithelium and to increase the vascular permeability [29,
30], which permits us to support its role in the chronic
inﬂammatory response [31].
In this work we studied the levels of galectin-10 in
nasal lavage ﬂuid (NLF), before and after nasal challenge
with L-aspirin. At baseline, the results evidenced higher
concentrations of galectin-10 in NLF from patients with
ASRD than in that from ATA and healthy subjects. After
the challenge with L-aspirin, the levels of galectin-10 in the
NLF behaved similarly; however, these diﬀerences were not
signiﬁcantbetweenASRDandATApatients.Wesuggestthat,
after L-aspirin nasal challenge, the eosinophils migrate to
the inﬂammation site in the nose, where they are activated
and acquire the capacity to secrete their granule contents,
increasing the levels of galectin-10 mainly in the ASRD
group. In addition, we recently observed an increase in the
concentrationofeosinophilcationicprotein(ECP)inNFLof
aspirin-sensitive subjects versus healthy controls after nasal
challenge with L-ASA [32], which conﬁrms the release of
mediators derived of eosinophils in the nasal ﬂuid.
Previously, Ghafouri and cols, in a proteomic study [22],
reported the presence of galectin-10 in nasal lavage ﬂuid
(NLF) from patients with seasonal allergic rhinitis. This
fact supports the possibility that galectin-10 plays a role
in the exacerbation of the inﬂammatory response, as well
as its potential utility in the correct diagnosis of ASRD.
However, in spite of this ﬁnding, the role(s) of this galectin
in the eosinophil, basophil, or associated inﬂammatory
processes still needs to be established. Nevertheless, the
results obtained in this work suggest the role of galectin-10
in the early inﬂammatory response in ASRD patients, which
could be a useful factor for the accurate diagnosis of the
disease.
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